Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
33 patients, including 31 oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study.
I · Intervention 중재 / 시술
definitive radiotherapy for the primary site and metastatic lesions between July 2012 and June 2022
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Acute adverse reactions of Grade 3+ were absent; chronic Grade 3 reactions were 3.0%. [CONCLUSION] Definitive radiotherapy for local/metastatic lesions demonstrates promising survival with manageable toxicity in omPCa.
[BACKGROUND] Few studies explore the role of definitive radiotherapy for prostate and all metastases in the treatment of low-burden oligometastatic prostate cancer (omPCa).
- 추적기간 38.8 months
APA
Xu B, Zhao X, et al. (2025). Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.. Frontiers in oncology, 15, 1662567. https://doi.org/10.3389/fonc.2025.1662567
MLA
Xu B, et al.. "Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.." Frontiers in oncology, vol. 15, 2025, pp. 1662567.
PMID
41256323 ↗
Abstract 한글 요약
[BACKGROUND] Few studies explore the role of definitive radiotherapy for prostate and all metastases in the treatment of low-burden oligometastatic prostate cancer (omPCa). This study aimed to investigate the potential survival benefit of this approach. Moreover, it is the first study to report the outcomes of definitive radiotherapy for local and distant metastatic lesions in patients with omPCa from China.
[METHODS] A retrospective analysis was conducted on patients with omPCa who received definitive radiotherapy for the primary site and metastatic lesions between July 2012 and June 2022. The inclusion criteria mandated fewer than 5 oligometastases, excluding regional lymph nodes by imaging examinations with no prior radiotherapy or radical prostatectomy for omPCa. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate survival rates. Univariate and multivariate analyses were conducted using Cox proportional hazards regression models.
[RESULTS] A total of 33 patients, including 31 oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2-70.6 months). The OS rates of 2-, 3-, and 5-year after treatment were 100.0%, 95.7%,and 81.2%, respectively. Factors correlating with poorer survival were pre-radiotherapy CRPC status, symptomatic lesions, and prior transurethral resection of the prostate (TURP). Multivariate analysis revealed potential associations: concomitant androgen deprivation therapy (ADT) or chemotherapy, non-CRPC status pre-radiotherapy. Lymph node and bone metastases together increased the risk of biochemical recurrence. Acute adverse reactions of Grade 3+ were absent; chronic Grade 3 reactions were 3.0%.
[CONCLUSION] Definitive radiotherapy for local/metastatic lesions demonstrates promising survival with manageable toxicity in omPCa.
[METHODS] A retrospective analysis was conducted on patients with omPCa who received definitive radiotherapy for the primary site and metastatic lesions between July 2012 and June 2022. The inclusion criteria mandated fewer than 5 oligometastases, excluding regional lymph nodes by imaging examinations with no prior radiotherapy or radical prostatectomy for omPCa. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate survival rates. Univariate and multivariate analyses were conducted using Cox proportional hazards regression models.
[RESULTS] A total of 33 patients, including 31 oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2-70.6 months). The OS rates of 2-, 3-, and 5-year after treatment were 100.0%, 95.7%,and 81.2%, respectively. Factors correlating with poorer survival were pre-radiotherapy CRPC status, symptomatic lesions, and prior transurethral resection of the prostate (TURP). Multivariate analysis revealed potential associations: concomitant androgen deprivation therapy (ADT) or chemotherapy, non-CRPC status pre-radiotherapy. Lymph node and bone metastases together increased the risk of biochemical recurrence. Acute adverse reactions of Grade 3+ were absent; chronic Grade 3 reactions were 3.0%.
[CONCLUSION] Definitive radiotherapy for local/metastatic lesions demonstrates promising survival with manageable toxicity in omPCa.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Spatiotemporal Mapping of Tumor Microenvironment Remodeling During Fiber-Optic Photothermal Therapy: A Multiparametric MRI Study in 4T1 Breast Cancer Xenografts.
- Application of metagenomic next-generation sequencing in diagnose the pulmonary infections caused by Aureobasidium melanogenum: A case report and review of the literature.
- Association between SGLT2 inhibitors and genital cancer: a meta-analysis and mendelian randomization study.
- Optimizing the choice between single- and bipedicled DIEP flaps: A strategy guided by 3D volumetrics and indocyanine green angiography.
- Fiber-type vulnerability and proteostasis reprogramming in skeletal muscle during pancreatic cancer cachexia.